Clinical Impact and Predictors of Aneurysmal Rebleeding in Poor-Grade Subarachnoid Hemorrhage: Results From the National POGASH Registry.


Journal

Neurosurgery
ISSN: 1524-4040
Titre abrégé: Neurosurgery
Pays: United States
ID NLM: 7802914

Informations de publication

Date de publication:
01 09 2023
Historique:
received: 24 11 2022
accepted: 27 01 2023
medline: 16 8 2023
pubmed: 4 4 2023
entrez: 3 4 2023
Statut: ppublish

Résumé

Scarce data are available regarding rebleeding predictors in poor-grade aneurysmal subarachnoid hemorrhage (aSAH). To investigate predictors and clinical impact of rebleeding in a national multicentric poor-grade aSAH. Retrospective analysis of prospectively collected data from the multicentric Poor Grade Aneurysmal Subarachnoid Hemorrhage Study Group (POGASH) registry of consecutive patients treated from January 1, 2015, to June 30th, 2021. Grading was defined as pretreatment World Federation of Neurological Surgeons grading scale IV-V. Ultra-early vasospasm (UEV) was defined as luminal narrowing of intracranial arteries not due to intrinsic disease. Rebleeding was defined as clinical deterioration with evidence of increased hemorrhage on subsequent computed tomography scans, fresh blood from the external ventricular drain, or deterioration before neuroradiological evaluation. Outcome was assessed by the modified Rankin Scale. Among 443 consecutive World Federation of Neurological Surgeons grades IV-V patients with aSAH treated within a median of 5 (IQR 4-9) hours since onset, rebleeding occurred in 78 (17.6%). UEV (adjusted odds ratio [OR] 6.8, 95% CI 3.2-14.4; P < .001) and presence of dissecting aneurysm (adjusted OR 3.5, 95% CI 1.3-9.3; P = .011) independently predicted rebleeding while history of hypertension (adjusted OR 0.4, 95% CI 0.2-0.8; P = .011) independently reduced its chances. 143 (32.3) patients died during hospitalization. Rebleeding emerged, among others, as an independent predictor of intrahospital mortality (adjusted OR 2.2, 95% CI 1.2-4.1; P = .009). UEV and presence of dissecting aneurysms are the strongest predictors of aneurysmal rebleeding. Their presence should be carefully evaluated in the acute management of poor-grade aSAH.

Sections du résumé

BACKGROUND
Scarce data are available regarding rebleeding predictors in poor-grade aneurysmal subarachnoid hemorrhage (aSAH).
OBJECTIVES
To investigate predictors and clinical impact of rebleeding in a national multicentric poor-grade aSAH.
METHODS
Retrospective analysis of prospectively collected data from the multicentric Poor Grade Aneurysmal Subarachnoid Hemorrhage Study Group (POGASH) registry of consecutive patients treated from January 1, 2015, to June 30th, 2021. Grading was defined as pretreatment World Federation of Neurological Surgeons grading scale IV-V. Ultra-early vasospasm (UEV) was defined as luminal narrowing of intracranial arteries not due to intrinsic disease. Rebleeding was defined as clinical deterioration with evidence of increased hemorrhage on subsequent computed tomography scans, fresh blood from the external ventricular drain, or deterioration before neuroradiological evaluation. Outcome was assessed by the modified Rankin Scale.
RESULTS
Among 443 consecutive World Federation of Neurological Surgeons grades IV-V patients with aSAH treated within a median of 5 (IQR 4-9) hours since onset, rebleeding occurred in 78 (17.6%). UEV (adjusted odds ratio [OR] 6.8, 95% CI 3.2-14.4; P < .001) and presence of dissecting aneurysm (adjusted OR 3.5, 95% CI 1.3-9.3; P = .011) independently predicted rebleeding while history of hypertension (adjusted OR 0.4, 95% CI 0.2-0.8; P = .011) independently reduced its chances. 143 (32.3) patients died during hospitalization. Rebleeding emerged, among others, as an independent predictor of intrahospital mortality (adjusted OR 2.2, 95% CI 1.2-4.1; P = .009).
CONCLUSION
UEV and presence of dissecting aneurysms are the strongest predictors of aneurysmal rebleeding. Their presence should be carefully evaluated in the acute management of poor-grade aSAH.

Identifiants

pubmed: 37010298
doi: 10.1227/neu.0000000000002467
pii: 00006123-202309000-00018
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

636-645

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © Congress of Neurological Surgeons 2023. All rights reserved.

Références

Starke RM, Connolly ES. Rebleeding after aneurysmal subarachnoid hemorrhage. 2011;15(2):241-246.
Stienen MN, Germans M, Burkhardt JK, et al. Predictors of in-hospital death after aneurysmal subarachnoid hemorrhage: analysis of a nationwide database (Swiss SOS [Swiss study on aneurysmal subarachnoid hemorrhage]). Stroke. 2018;49(2):333-340.
Broderick JP, Brott TG, Duldner JE, Tomsick T, Leach A. Initial and recurrent bleeding are the major causes of death following subarachnoid hemorrhage. Stroke. 1994;25(7):1342-1347.
Vergouwen MD, Jong-Tjien-Fa AV, Algra A, Rinkel GJ. Time trends in causes of death after aneurysmal subarachnoid hemorrhage: a hospital-based study. Neurology. 2016;86(1):59-63.
Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al.; American Heart Association Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology; Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43(6):1711-1737.
Germans MR, Coert BA, Vandertop WP, Verbaan D. Time intervals from subarachnoid hemorrhage to rebleed. J Neurol. 2014;261(7):1425-1431.
Ohkuma H, Tsurutani H, Suzuki S. Incidence and significance of early aneurysmal rebleeding before neurosurgical or neurological management. Stroke. 2001;32(5):1176-1180.
Post R, Germans MR, Tjerkstra MA, et al. Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA): a randomised controlled trial. Lancet. 2021;397(10269):112-118.
Phillips TJ, Dowling RJ, Yan B, Laidlaw JD, Mitchell PJ. Does treatment of ruptured intracranial aneurysms within 24 hours improve clinical outcome? Stroke. 2011;42(7):1936-1945.
Park J, Woo H, Kang DH, et al. Formal protocol for emergency treatment of ruptured intracranial aneurysms to reduce in-hospital rebleeding and improve clinical outcomes. J Neurosurg. 2015;122(2):383-391.
Tang C, Zhang TS, Zhou LF. Risk factors for rebleeding of aneurysmal subarachnoid hemorrhage: a meta-analysis. PLoS One. 2014;9(6):e99536.
Laidlaw JD, Siu KH. Ultra-early surgery for aneurysmal subarachnoid hemorrhage: outcomes for a consecutive series of 391 patients not selected by grade or age. J Neurosurg. 2002;97(2):250-258; discussion 247-249.
Lu VM, Graffeo CS, Perry A, et al. Subarachnoid hemorrhage rebleeding in the first 24 h is associated with external ventricular drain placement and higher grade on presentation: cohort study. J Clin Neurosci. 2020;81:180-185.
Report of World Federation of neurological Surgeons committee on a universal subarachnoid hemorrhage grading scale. J Neurosurg. 1988;68(6):985-986.
Chiang VLS, Claus EB, Awad IA. Toward more rational prediction of outcome in patients with high-grade subarachnoid hemorrhage. Neurosurgery. 2000;46(1):28-35. discussion 35-36.
Claassen J, Carhuapoma JR, Kreiter KT, Du EY, Connolly ES, Mayer SA. Global cerebral edema after subarachnoid hemorrhage: frequency, predictors, and impact on outcome. Stroke. 2002;33(5):1225-1232.
Suwatcharangkoon S, Meyers E, Falo C, et al. Loss of consciousness at onset of subarachnoid hemorrhage as an important marker of early brain injury. JAMA Neurol. 2016;73(1):28-35.
Claassen J, Bernardini GL, Kreiter K, et al. Effect of cisternal and ventricular blood on risk of delayed cerebral ischemia after subarachnoid hemorrhage: the Fisher scale revisited. Stroke. 2001;32(9):2012-2020.
Mizutani T, Miki Y, Kojima H, Suzuki H. Proposed classification of nonatherosclerotic cerebral fusiform and dissecting aneurysms. Neurosurgery. 1999;45(2):253-259; discussion 259-260.
Vergouwen MD, Vermeulen M, van Gijn J, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke. 2010;41(10):2391-2395.
Tykocki T, Czyż M, Machaj M, Szydlarska D, Kostkiewicz B. Comparison of the timing of intervention and treatment modality of poor-grade aneurysmal subarachnoid hemorrhage. Br J Neurosurg. 2017;31(4):430-433.
Zhao B, Rabinstein A, Murad MH, Lanzino G, Panni P, Brinjikji W. Surgical and endovascular treatment of poor-grade aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. J Neurosurg Sci. 2017;61(4):403-415.
Al-Mufti F, Mayer SA, Kaur G, et al. Neurocritical care management of poor-grade subarachnoid hemorrhage: unjustified nihilism to reasonable optimism. Neuroradiol J. 2021;34(6):542-551.
Wostrack M, Sandow N, Vajkoczy P, et al. Subarachnoid haemorrhage WFNS grade V: is maximal treatment worthwhile? Acta Neurochir (Wien). 2013;155(4):579-586.
Zhao B, Fan Y, Xiong Y, et al.; AMPAS Study Group. Aneurysm rebleeding after poor-grade aneurysmal subarachnoid hemorrhage: predictors and impact on clinical outcomes. J Neurol Sci. 2016;371:62-66.
Tack RW, Vergouwen MD, van der Schaaf I, van der Zwan A, Rinkel GJ, Lindgren AE. Preventable poor outcome from rebleeding by emergency aneurysm occlusion in patients with aneurysmal subarachnoid haemorrhage. Eur Stroke J. 2019;4(3):240-246.
Darkwah Oppong M, Gümüs M, Pierscianek D, et al. Aneurysm rebleeding before therapy: a predictable disaster? J Neurosurg. 2019;131(5):1473-1480.
Bailes JE, Spetzler RF, Hadley MN, Baldwin HZ. Management morbidity and mortality of poor-grade aneurysm patients. J Neurosurg. 1990;72(4):559-566.
Baldwin ME, Macdonald RL, Huo D, et al. Early vasospasm on admission angiography in patients with aneurysmal subarachnoid hemorrhage is a predictor for in-hospital complications and poor outcome. Stroke. 2004;35(11):2506-2511.
Al-Mufti F, Roh D, Lahiri S, et al. Ultra-early angiographic vasospasm associated with delayed cerebral ischemia and infarction following aneurysmal subarachnoid hemorrhage. J Neurosurg. 2017;126(5):1545-1551.
Qureshi AI, Sung GY, Suri MAK, Straw RN, Guterman LR, Hopkins LN. Prognostic value and determinants of ultraearly angiographic vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery. 1999;44(5):967-973; discussion 973-974.
Bederson JB, Levy AL, Hong Ding W, et al. Acute vasoconstriction after subarachnoid hemorrhage. Neurosurgery. 1998;42(2):352-362.
Wilkins RH. Aneurysm rupture during angiography: does acute vasospasm occur? Surg Neurol. 1976;5(5):299-303.
Al-Mufti F, Amuluru K, Smith B, et al. Emerging markers of early brain injury and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage. World Neurosurg. 2017;107:148-159.
Sim SY, Chung J, Shin YS. Are blood blister-like aneurysms a specific type of dissection? A comparative study of blood blister-like aneurysms and ruptured mizutani type 4 vertebral artery dissections. J Korean Neurosurg Soc. 2014;56(5):395-399.
Ogawa A, Suzuki M, Ogasawara K. Aneurysms at nonbranching sites in the supraclinoid portion of the internal carotid artery: internal carotid artery trunk aneurysms. Neurosurgery. 2000;47(3):578-586; discussion 583-586.
De Marchis GM, Lantigua H, Schmidt JM, et al. Impact of premorbid hypertension on haemorrhage severity and aneurysm rebleeding risk after subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 2014;85(1):56-59.
van Donkelaar CE, Bakker NA, Veeger NJ, et al. Predictive factors for rebleeding after aneurysmal subarachnoid hemorrhage: rebleeding aneurysmal subarachnoid hemorrhage study. Stroke. 2015;46(8):2100-2106.
Cagnazzo F, Gambacciani C, Morganti R, Perrini P. Aneurysm rebleeding after placement of external ventricular drainage: a systematic review and meta-analysis. Acta Neurochir (Wien). 2017;159(4):695-704.
Schmidt EA, Silva S, Albucher JF, et al. Cerebral hemodynamic changes induced by a lumbar puncture in good-grade subarachnoid hemorrhage. Cerebrovasc Dis Extra. 2012;2(1):52-62.
Münch EC, Bauhuf C, Horn P, Roth HR, Schmiedek P, Vajkoczy P. Therapy of malignant intracranial hypertension by controlled lumbar cerebrospinal fluid drainage. Crit Care Med. 2001;29(5):976-981.
van Lieshout JH, Pumplün I, Fischer I, et al. Volume of cerebrospinal fluid drainage as a predictor for pretreatment aneurysmal rebleeding. J Neurosurg. 2018;128(6):1778-1784.

Auteurs

Pietro Panni (P)

Department of Neuroradiology, Interventional Neuroradiology Division, San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy.
Department of Neurosurgery, San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy.

Lucia Riccio (L)

Department of Neurosurgery, San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy.

Roberta Cao (R)

Department of Neuroradiology, Interventional Neuroradiology Division, San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy.

Alessandro Pedicelli (A)

Institute of Radiological Sciences, Fondazione Policlinico Universitario A. Gemelli, IRCCS Catholic University of Rome, Rome, Italy.

Enrico Marchese (E)

Department of Neurosurgery Fondazione Policlinico Universitario A. Gemelli, IRCCS Catholic University of Rome, Rome, Italy.

Anselmo Caricato (A)

Department of Anesthesia and Critical Care Medicine Fondazione Policlinico Universitario A.Gemelli IRCCS Catholic University of Rome, Rome, Italy.

Alberto Feletti (A)

Institute of Neurosurgery, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.

Mattia Testa (M)

Institute of Neurosurgery, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.

Paolo Zanatta (P)

Anesthesia and Intensive Care A, Integrated University Hospital, Verona, Italy.

Nicola Gitti (N)

Department of Anesthesia, Critical Care and Emergency, Spedali Civili University Hospital, Brescia, Italy.

Simone Piva (S)

Department of Anesthesia, Critical Care and Emergency, Spedali Civili University Hospital, Brescia, Italy.
Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.

Dikran Mardighian (D)

Department of Neuroradiology Spedali Civili University Hospital, Brescia, Italy.

Vittorio Semeraro (V)

Department of Radiology, SS Annunziata Hospital, Taranto, Italy.

Giordano Nardin (G)

Department of Critical Care, SS Annunziata Hospital, Taranto, Italy.

Emilio Lozupone (E)

Department of Neuroradiology, Vito-Fazzi Hospital, Lecce, Italy.

Giafranco Paiano (G)

Department of Anaesthesia and Critical Care, Vito-Fazzi Hospital, Lecce, Italy.

Edoardo Picetti (E)

Department of Anesthesia and Intensive Care, Parma University Hospital, Italy.

Vito Montanaro (V)

Department of Anesthesia and Intensive Care, Parma University Hospital, Italy.

Massimo Petranca (M)

Department of Anesthesia and Intensive Care, Parma University Hospital, Italy.

Carlo Bortolotti (C)

Department of Neurosurgery, IRCCS Institute of Neurological Sciences "Bellaria", Bologna, Italy.

Antonino Scibilia (A)

Department of Neurosurgery, IRCCS Institute of Neurological Sciences "Bellaria", Bologna, Italy.

Luigi Cirillo (L)

Department of Neuroradiology, IRCCS Institute of Neurological Sciences "Bellaria", Bologna, Italy.

Andrea Luigi Lanterna (AL)

Department of Neurosurgery, Papa Giovanni XXIII Hospital, Bergamo, Italy.

Alessandro Ambrosi (A)

, School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.

Pietro Mortini (P)

Department of Neurosurgery, San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy.

Luigi Beretta (L)

Department of Neurocritical Care San Raffaele University Hospital, Milan, Italy.

Andrea Falini (A)

Department of Neuroradiology, Interventional Neuroradiology Division, San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH